Search
Results: 1
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Jonathan Steinfeld, Eric S Bradford, Judith Brown, Stephen Mallett, Steven W Yancey, Praveen Akuthota, Maria C Cid, Gerald J Gleich, David Jayne, Paneez Khoury, Carol A Langford, Peter A Merkel, Frank Moosig, Ulrich Specks, Peter F Weller, Michael E Wechsler
Jun 28, 2019
BACKGROUND: In a recent phase III trial (NCT02020889) 53% of mepolizumab-treated versus 19% of placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) achieved protocol-defined remission. OBJECTIVE: We...
Churg-Strauss syndrome Eosinophilic granulomatosis with polyangiitis IL-5 Eosinophils mepolizumab Vasculitis Adult Antibodies Monoclonal Humanized Double-Blind Method Eosinophilic Granuloma Eosinophils Female Granulomatosis with polyangiitis Humans Interleukin-5 Leukocyte Count Male Middle Aged Placebos Prednisolone Treatment Outcome